Latest Kaiser Health News Stories
On Season 3, Episode 2 of the podcast “An Arm and a Leg,” an Illinois woman harnesses a lifetime of experience — and frustration — with health care finances to help other people solve their medical bill problems.
An organization that helps nearly 4,000 California dialysis patients pay for their insurance is threatening to cut off aid in January because of a new law that is expected to reduce dialysis industry profits. Patients fear they won’t be able to afford their life-saving treatment.
A long illness creates a real risk: that the relationship will be undermined and essential emotional connections lost.
Those who rely on plug-in health devices or medicine that requires refrigeration are scrambling to find ways to avoid potentially life-threatening disruptions now and in future fire season shutdowns.
Katie West, an American health researcher who has lived in Germany the past three years, hasn’t mastered the language and misses her family. But not having to worry about the cost of her lifesaving medication makes it OK.
Health experts say the little-used benefit represents a lost opportunity for older adults to improve their health — and for the program to save money by preventing costly complications from diabetes and chronic kidney disease.
One out of every 13 older Americans struggles to find enough food to eat while the federal program intended to help hasn’t kept pace with the graying population.
As the Indian government reluctantly loosens its prescription opioid laws after decades of lobbying by palliative care advocates desperate to ease their patients’ pain, the nation’s sprawling, cash-fed health care system is ripe for misuse.
What began in India as a populist movement to bring inexpensive morphine to the diseased and dying poor has paved the way for a booming pain management industry. Now, new customers are being funneled to U.S. drugmakers bedeviled by a government crackdown back home.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Dialysis companies are fighting a bill in the California legislature that could disrupt their business model. Their weapons: campaign cash and a sophisticated public relations campaign.
What changes are needed to bring home dialysis to more patients — especially older adults, the fastest-growing group of patients with serious, irreversible kidney disease? We asked nephrologists, patient advocates and dialysis company officials for their thoughts.
People with diabetes say they’ve been waiting for years for better technology to manage their chronic condition. Tired of waiting, some tech-savvy, do-it-yourselfers are constructing their own devices using open-source programming instructions.
California’s stem cell agency, created by a $3 billion bond measure 15 years ago, is almost out of money. Its supporters plan to ask voters for even more funding next year, even though no agency-funded treatments have been approved for widespread use.
After journalists investigate, Fresenius, one of the largest dialysis providers in the U.S., has agreed to waive a half-million-dollar bill. Sovereign Valentine, from Plains, Mont., said it’s a “huge relief.”
When it comes to physician-administered infusion drugs, doctors sometimes have a financial reason for their choice and patients often aren’t aware of cheaper options.
Amazon, along with a host of other technology companies, is working on ways to use its smart speaker devices to bring a range of health care services into your home.
Only about 12% of dialysis patients get their treatment at home and the initiative aims to dramatically increase that number and move patients out of costly dialysis centers. It would also add provisions to boost the annual number of kidneys available for transplants.
Though the candidates tended to agree on the end goal of universal coverage, differences emerged over how to get there.
As people advance in age, the expectations for what constitutes good health change. People focus on positive emotions and satisfaction with life, while physical ailments play a less important role.